These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 28118224)

  • 21. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice.
    Yasuda M; Gan L; Chen B; Kadirvel S; Yu C; Phillips JD; New MI; Liebow A; Fitzgerald K; Querbes W; Desnick RJ
    Proc Natl Acad Sci U S A; 2014 May; 111(21):7777-82. PubMed ID: 24821812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.
    Yasuda M; Desnick RJ
    Mol Genet Metab; 2019 Nov; 128(3):332-341. PubMed ID: 30737139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and treatment of the hepatic porphyrias.
    Lecha M; Herrero C; Ozalla D
    Dermatol Ther; 2003; 16(1):65-72. PubMed ID: 12919129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
    Sardh E; Harper P
    J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Excretion pattern of faecal coproporphyrin isomers I-IV in human porphyrias.
    Jacob K; Doss MO
    Eur J Clin Chem Clin Biochem; 1995 Dec; 33(12):893-901. PubMed ID: 8845420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematologic aspects of the porphyrias.
    Sassa S
    Int J Hematol; 2000 Jan; 71(1):1-17. PubMed ID: 10729988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.
    Balwani M
    Mol Genet Metab; 2019 Nov; 128(3):298-303. PubMed ID: 30704898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic porphyrias.
    Scarlett YV; Brenner DA; Bloomer JR
    Clin Liver Dis; 1998 Feb; 2(1):77-102, vi. PubMed ID: 15560047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation in human
    Yien YY; Ducamp S; van der Vorm LN; Kardon JR; Manceau H; Kannengiesser C; Bergonia HA; Kafina MD; Karim Z; Gouya L; Baker TA; Puy H; Phillips JD; Nicolas G; Paw BH
    Proc Natl Acad Sci U S A; 2017 Sep; 114(38):E8045-E8052. PubMed ID: 28874591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy.
    Majeed CN; Ma CD; Xiao T; Rudnick S; Bonkovsky HL
    Drug Des Devel Ther; 2022; 16():1827-1845. PubMed ID: 35734365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Management of erythropoetic and hepatic porphyrias].
    Gundling F; Mössner J
    Dtsch Med Wochenschr; 2005 Feb; 130(7):335-9. PubMed ID: 15712021
    [No Abstract]   [Full Text] [Related]  

  • 32. Givosiran: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):335-339. PubMed ID: 32034693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Porphyrias-what is verified?].
    Stölzel U; Kubisch I; Stauch T
    Internist (Berl); 2018 Dec; 59(12):1239-1248. PubMed ID: 30328490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in understanding the pathogenesis of congenital erythropoietic porphyria.
    Di Pierro E; Brancaleoni V; Granata F
    Br J Haematol; 2016 May; 173(3):365-79. PubMed ID: 26969896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What hematologists need to know about acute hepatic porphyria.
    Balwani M
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):858-861. PubMed ID: 27930636
    [No Abstract]   [Full Text] [Related]  

  • 36. [Acute porphyria].
    Petersen NE; Brock A
    Tidsskr Nor Laegeforen; 2000 May; 120(12):1421-3. PubMed ID: 10851939
    [No Abstract]   [Full Text] [Related]  

  • 37. [New therapeutic option for acute hepatic porphyrias].
    Stölzel U; Schuppan D
    Dtsch Med Wochenschr; 2021 Aug; 146(15):955-958. PubMed ID: 34344029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances in the identification of enzyme deficiencies in the porphyrias.
    Elder GH
    Br J Dermatol; 1983 Jun; 108(6):729-34. PubMed ID: 6344903
    [No Abstract]   [Full Text] [Related]  

  • 39. Givosiran to treat acute porphyria.
    Honor A; Rudnick SR; Bonkovsky HL
    Drugs Today (Barc); 2021 Jan; 57(1):47-59. PubMed ID: 33594389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives.
    Marcacci M; Ricci A; Cuoghi C; Marchini S; Pietrangelo A; Ventura P
    Orphanet J Rare Dis; 2022 Apr; 17(1):160. PubMed ID: 35392955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.